Onvansertib in combination with both chemo/bev regimens was well-tolerated. There were no major or unexpected toxicities observed and no additive adverse events. Grade 3 or higher adverse events were ...
The authors say delivering FOLFOX via transarterial infusion could be a “perfect option for treating intrahepatic cholangiocarcinoma before patients receive targeted therapy, immunotherapy, or ...
Please provide your email address to receive an email when new articles are posted on . The phase 3 randomized study, presented at ASCO Annual Meeting, evaluated the overall response rate of ...
Phase II study of E7820 in combination with cetuximab in subjects (pts) with metastatic and refractory colorectal cancer (CRC). Background: Motesanib is an oral inhibitor of VEGF, PDFG, and Kit ...
Amivantamab combined with FOLFOX or FOLFIRI showed a 51% overall response rate in RAS/BRAF wild-type mCRC patients, with a median progression-free survival of 9.2 months. The study highlighted notable ...
Racial disparity trends in clinical presentation and outcomes in colorectal cancer: Findings from an urban university hospital. Background: A combination of leucovorin (LV) and fluorouracil (FU) with ...
SEQUOIA compared efficacy and safety of adding pegilodecakin (PEG), a pegylated recombinant human interleukin (IL)-10, with folinic acid, fluorouracil, and oxaliplatin (FOLFOX) in patients following ...
Roche Release: Results Show XELOX Provides Equivalent Overall Patient Survival Compared To FOLFOX In Advanced Colorectal Cancer NUTLEY, N.J., Jan. 22 -- Overall survival results from an international, ...
In the movement towards individualized treatment regimens, Rothenberg et al. validate XELOX as another available systemic therapy for patients being treated with second-line treatment for metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results